Cochlear Ltd
Company Profile
Business description
Cochlear is the leading cochlear implant device manufacturer with around 60% global market share. Developed markets contribute 80% of group revenue where cochlear implants are the standard of care for children with severe to profound hearing loss. The company also actively targets the growing cohort of seniors in developed markets. Tender-oriented emerging markets contribute the remaining 20% of group revenue. Main products include cochlear implants, bone-anchored hearing aids, and associated sound processors. In fiscal 2020, 49% of revenue came from the Americas, 35% from Europe, the Middle East, and Africa, and 16% from the Asia-Pacific segment.
Contact
1 University Avenue
Macquarie University
SydneyNSW2109
AUST: +61 294286555
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
30 June 2026
Employees
5,500
Cochlear Ltd News & Analysis
stocks
Are investors too bearish on Australian equities?
stocks
Cochlear earnings: Shares overvalued as demand softens
personal-finance
Bookworm: This ASX name meets many of Terry Smith’s criteria
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,236.50 | 29.80 | 0.32% |
| CAC 40 | 8,157.29 | 43.59 | -0.53% |
| DAX 40 | 24,118.89 | 5.32 | -0.02% |
| Dow JONES (US) | 47,522.12 | 109.88 | -0.23% |
| FTSE 100 | 9,760.06 | 3.92 | 0.04% |
| HKSE | 26,282.69 | 63.45 | -0.24% |
| NASDAQ | 23,581.14 | 377.33 | -1.57% |
| Nikkei 225 | 51,762.67 | 437.06 | 0.85% |
| NZX 50 Index | 13,500.69 | 41.40 | 0.31% |
| S&P 500 | 6,822.34 | 68.25 | -0.99% |
| S&P/ASX 200 | 8,942.40 | 29.20 | 0.33% |
| SSE Composite Index | 3,986.90 | 29.43 | -0.73% |